CRASH-3   

Clinical Randomisation of an Antifibrinolytic in Significant Head Injury       

 
crash.png

Chief Investigator: Professor Ian Robert

Principle Investigator (LTHT): Dr Taj Hassan

Site: Leeds General Infirmary

CRASH-3 Website


 

Start Date: August 2013

End Date: January 2019

The Aim

The CRASH-3 trial will provide evidence about the effect of tranexamic acid (TXA) on mortality and disability in patients with traumatic brain injury (TBI). 

The Trial

  • The CRASH-3 trial is a large, international randomised, placebo controlled trial, to assess the safety and effect of the administration of TXA in patients with TBI on mortality and morbidity.
  • Inclusion criteria
    • Adults with TBI
    • Within three hours of injury
    • With any intracranial bleeding on CT scan or who have a GCS of 12 or less, and have no significant extra-cranial haemorrhage, are eligible for inclusion
  • Exclusion criteria
    • Those for whom antifibrinolytic agents are thought to be clearly indicated or clearly contra-indicated
  • Treatment will be allocated randomly
 
red banner.jpg